Who makes OMP-54F28 with Sorafenib?

OMP-54F28 with Sorafenib is developed by OncoMed Pharmaceuticals, Inc..

What development phase is OMP-54F28 with Sorafenib in?

OMP-54F28 with Sorafenib is in Phase 1.

Last reviewed 2026-05-15 · How we verify

OMP-54F28 with Sorafenib

OncoMed Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	OMP-54F28 with Sorafenib
Also known as	OMP-54F28, Sorafenib
Sponsor	OncoMed Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OMP-54F28 with Sorafenib CI brief — competitive landscape report
OMP-54F28 with Sorafenib updates RSS · CI watch RSS
OncoMed Pharmaceuticals, Inc. portfolio CI